ESC and EACTS Issue Consensus on Antithrombotic Therapy After CABG
This joint ESC/EACTS clinical consensus statement addresses antithrombotic management after coronary artery bypass grafting to reduce graft occlusion and thrombotic complications.
📅 Journal publication: May 21, 2026·Last updated: Aug 24, 2026
ESC/EACTS Consensus StatementEuropean Society of CardiologyEuropean Association for Cardio-Thoracic Surgerycoronary artery bypass graftantithrombotic therapyantiplateletsanticoagulantsCardiology / Anticoagulation
Background Information
Balance risks: Antithrombotic therapy post-bypass under scrutiny.
Antithrombotic therapy post-coronary artery bypass grafting is crucial to prevent complications like graft occlusion. Aspirin is standard, but dual antiplatelet therapy or combined therapy is suggested for high-risk patients, balancing bleeding versus thrombotic risks. Tailor therapy to individual risk profiles and reassess regularly; highlights consensus and areas needing more research. Match antithrombotic therapy to patient risk post-coronary artery bypass.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Sandner S, Gaudino M, Agewall S, Bonalumi G, Bonaros N, Czerny M, Jeppsson A, Milojevic M, Niessner A, Parolari A, Sulzgruber P, Tamargo J, Thielmann M, Wassmann S, Zientara A, Dobrev D
Citation:Sandner S, Gaudino M, Agewall S, et al. Antithrombotic therapy after coronary artery bypass graft surgery: a Clinical Consensus Statement of the ESC Working Group on Cardiovascular Surgery, the ESC Working Group on Cardiovascular Pharmacotherapy, and the European Association for Cardio-Thoracic Surgery (EACTS). European heart journal. 2026;47(20):2419-2436. doi:10.1093/eurheartj/ehaf423